Member Info for Hulver

Pretty sure that when Amgen bowed out Vlad tweeted "Another one bites the dust" - and a big one at that.

And so here, we might be last man standing - the VisionOn man?

But not at that discount and dilution.

I haven't considered the warrants impact on Briacell's dilution, but even without that the shares are issued at 58% discount to share price a week ago $1.25 v $3. Just like Hemo has done in the past, massive discounts and not the first time for them either. So an already decimated share price is 75% down from last week to $0.75 and that's after the announcement of seemingly good Phase 2 and Phase 3 results:

https://www.globenewswire.com/news-release/2025/07/15/3115474/0/en/BriaCell-Adds-Mayo-Clinic-to-Phase-3-Study-in-Metastatic-Breast-Cancer.html

Who is behind Prevail?

Hemo have very little in the way of progress/results to compare to that yet (unless we have two unreported cures).

Why be in a rush to offload the final 2%?

I note again, amongst all the positive clinical trial news of recent weeks, today this happened on Briacell (in which Prevail Partners are also investors, Hemo has shown too many similarities to Briacell for my liking)

https://www.globenewswire.com/news-release/2025/07/15/3115965/0/en/BriaCell-Therapeutics-Announces-Pricing-of-15-million-Public-Offering.html

I note that the Pipeline table on HEMO's website has been updated (not sure when, but quite recently I think, last month or so).

https://hemogenyx.com/pipeline/

New indications for Pediatric AML and BPDCN have been added for HG-CT-1

Some additional details have been inserted regarding the indications for CBR including GBM, multiple myeloma and epithelial ovarian carcinoma. Some of these were mentioned in the Boston pitch for CBR in Sep 2023.

I also noted that one of the employees who left in June seemed to have undertaken establishment and further development work on HEMO's in-house SGM3 humanised mouse models in the past three years.

But we had the consolidation for the US institutional investors - there doesn't seem to have been any US investors there!

Moral deficit created, that's all.

From this (see Vlad's post three months' ago)

https://www.linkedin.com/posts/jillian-handel_proud-to-be-a-part-of-this-team-activity-7305938300165316608-bnrP

to that

Is/was there actually a requirement to announce P3 - given that neither P1 or P2 announcements had any impact on SP? Could they already have infused patient 3 (and potentially almost/also patient 4 by now)? Presumably they aren't going to inform about every patient and such updates must stop somewhere. We knew when HG-CT-1 was being manufactured for P3 (end May), is there anything to suggest that things haven't progressed as expected since then (and that's not a 68 day interval, but more like 35 - 40 days).

The next update might be to do with the commencement of the child cohort?

With regard to P1 and P2, presumably if they were physically well prior to the onset of their AML, with no other underlying conditions, then there is potentially a very positive longer term outcome for them if HG-CT-1 has efficacy against FLT-3 and reduces the AML or even as was suggested as a possibility, cures it. I wonder is this taken into account when selecting patients for the trial.

For younger patients, I would suggest that they are more likely to only be suffering from AML.

Https://www.investing.com/news/stock-market-news/briacell-therapeutics-stock-tumbles-after-announcing-public-offering-93CH-4128244

I've been watching what they've done to Briacell over the past few years (Prevail involvement), similar story of positive scientific results through trials, and then falling share price, share consolidations, and they have done this today:

https://www.investing.com/news/stock-market-news/briacell-therapeutics-stock-tumbles-after-announcing-public-offering-93CH-4128244after this announcement, today

https://www.biospace.com/press-releases/briacell-phase-2-survival-achievement-52-of-patients-surpass-one-year-milestone-in-metastatic-breast-cancer

meanwhile, sitting ducks are we?

Not sure these are 'old blood'; and I haven't yet noticed any adverts for replacements 'new blood'.

Agree it could be trimming costs that can be trimmed - but then that could be interpreted as a sideways/backwards step.

Does it fit with the objective? - BRINGING BREAKTHROUGH THERAPIES TO PATIENTS FOR THE TREATMENT OF LIFE-THREATENING DISEASES

Another scientist (perhaps much less experienced than the previous two) has left. Jillian Handel now with Neptune Bio. She is a recent departure only posting within the last few months how great it was to be part of the Hemo team. All three seem on the R&D side. So ihave the finished with or cut back on R&D - are the products as ready as they need to be?

Some things that puzzle:

The loss of three scientists doesn't seem to fit with the rapid expansion portrayed in the press coverage when they moved into Mink Building.

The apparent lack of a succession plan at board or scientist level does not seem to infer further expansion or long term

HEMO-CAR-T - name switched to HG-CT-1

AGM brought forward a month..

Pediatric clearance RNS: "Importantly, it also reinforces the value of Company's robust intellectual property portfolio, which underpins our pipeline and supports long-term strategic growth." - is STRATEGIC growth would appear to be suggesting JV/partnership?

Who's behind the funding through Prevail Partners Fund (never got to the bottom of that)?

What is to happen with CDX and CBR - if they are ready? The recent RNS's indicate that positive results from the HG-CT-1 trials supports also the pipeline technologies.

We've never been provided with any results from the CBR tests undertaken at a (US?) government connected BSL3 facility?

How long will it take to obtain the IRB approvals and select the first pediatric candidate (if it was happening at MD Anderson) you'd think it would not take that long. Perhaps another site is joining for the pediatric trial.

If successful could there be competitors for HG-CT-1?

Meanwhile, the science seemingly is marching forwards.

If HEMO CAR-T proves half as durable as STU's occupation of this board, then I think we'll be just fine.

Something's afoot.

Just an update on 'friend' and former Hemo 'investor' Ron Bauer

https://www.justice.gov/usao-sdny/pr/international-stock-manipulator-sentenced-20-months-pump-and-dump-scheme

https://www.stephensonharwood.com/news/pump-and-dump-share-ramping-guilty-plea-in-$100-million-share-manipulation-scheme

Seems an extraordinarily light sentence and fine.

First, Michael Haugbro seemed to announce leaving June 2025;

Now it might appear that Satish Dhingra too, ceased working for Hemo June 2025

It seemed to me that both were involved in the manufacturing process or at least in getting HEMO to the point of manufacturing for the clinical trial.

"Satish K. Dhingra, PhD - Ardsley, New York, United States

LinkedIn · Satish K. Dhingra, PhD

470+ followers

Experience. HEMOGENYX LLC Graphic. Senior scientist. HEMOGENYX LLC. May 2022 - Jun 2025 3 years 2 months. New york. CAR-T Cell Therapy Translation (R/R AML):"

And this webinar, given by Nicholas Short, from May (post the commencement of HG-CT-1 trials) - simple sign in to watch:

https://healthtree.org/aml/community/events/may2025-acute-myeloid-leukemia-flt3

Posting again, latest from Nicholas Short on this subject:

https://www.vjhemonc.com/video/jjdposxlstq-long-term-survival-and-relapse-patterns-in-flt3-mutated-aml-treated-with-frontline-triplet-therapy/

Wondering what happened to CBR?

The International Preliminary Report on Patentability was issued 30/08/2024.

https://patentscope.wipo.int/search/docs2/pct/WO2023168292/pdf/hBQVJojIBesJ8T1cMRgMIptw_8idJlTcvPhRSKsEAuE

Very small team at Hemo though, without him are they still compliant to be able to continue manufacturing for the trial?

Presumably there are requirements that have to be met, and a loss at that level may have to be reported to the licencing authorities, with the succession plan approved?

From my recollection:

Vlad discovered Huphec - the exclusive rights to which from Cornell were given up by Hemo in Feb 2025 - to save money?

It was Koen van Gesien's awareness, and benevolence that suggested he should look into using his CDX construct for AML, which lead to CAR-T.

Lilly scientists had to enhance CDX to reach a certain standard, but then it was announced in Sep 2024 that Hemo's scientists had created a better version of CDX (and I think it was Elina that was working on that, whilst others were focussing on CAR-T)

CBR only made significant advance after Michael Haugbro arrived at Hemo (I believe he must have made some significant contribution to its effectiveness as he was named in the patent application - not that long after joining HEMO, and he advanced rapdicly to senior scientist).

Finally, I think it is possible Michale may have been known to Vlad from earlier placements when Vlad was at Cornell; and how he was sourced.

Maybe he has outgrown Hemo, and needs a bigger challenge.

In any case, it's worrying that it has come to this.

Michael Haugbro, Senior Scientist (Linkedin now states Nov 2022 - June 2025)

"I am a protein chemist by training with 10+ years of research experience in peptide and peptidomimetic chemistry, protein semi-synthesis, in vitro biochemistry and biophysics, mammalian cell culture and cell-based assays, and immunology. Over the last 4 years, I was a leader on the team which transitioned the autologous CAR-T therapy at Hemogenyx Pharmaceuticals from pre-clinical development into a Phase I clinical trial. I am looking for positions in NY/NJ in R&D for biologics and cell therapies, manufacturing leadership or quality assurance for clinical biopharma companies, and science writing."

Ex Princeton University, this will be a massive loss to HEMO; especially with the future alleged promise of CBR and CDX.

Vlad has always spoken so highly of his team of scientists; I wonder what has caused this and is it isolated or part of a something more significant at the company.

Whatever happened to this issue of shares for work to be done by Prevail - as far as I can see no shares have been issued for it yet; and yet nothing to report that the strategic investment as announced was amended or cancelled.

https://www.lse.co.uk/rns/HEMO/strategic-investment-from-prevail-partners-llc-re84v9fv90tzezc.html

Unusual activity indeed.